Rapamycin is the latest in a series of new immunosuppressants. Because of its unique capacity to inhibit lymphokine signal transduction, the immune-modulating potentials of rapamycin appear to be different from the antecedent agents, Cyclosporine and FK506. This influence on the effector arm of the immune-response makes Rapamycin a suitable candidate for multiple-drug therapy in combination with Cyclosporine which acts earlier in the immunoresponse process. Rapamycin, unlike Cyclosporine and FK506, has been shown to affect B-cell functions and T-cell - B-cell signal pathways. The effect on antibody synthesis may explain Rapamycin induced unresponsiveness.
IMMUNOPHARMACOLOGY OF RAPAMYCIN / M. Ferraresso, B. Kahan. - In: EOS. - ISSN 0392-6699. - 12:4(1992), pp. 252-255.
IMMUNOPHARMACOLOGY OF RAPAMYCIN
M. FerraressoPrimo
;
1992
Abstract
Rapamycin is the latest in a series of new immunosuppressants. Because of its unique capacity to inhibit lymphokine signal transduction, the immune-modulating potentials of rapamycin appear to be different from the antecedent agents, Cyclosporine and FK506. This influence on the effector arm of the immune-response makes Rapamycin a suitable candidate for multiple-drug therapy in combination with Cyclosporine which acts earlier in the immunoresponse process. Rapamycin, unlike Cyclosporine and FK506, has been shown to affect B-cell functions and T-cell - B-cell signal pathways. The effect on antibody synthesis may explain Rapamycin induced unresponsiveness.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
